Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. The combination of thiotepa, busulfan, and fludarabine or FluCy and low‐dose total body irradiation were the most common conditioning regimen used in MAC and RIC setting, respectively. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A et al. There is a learning curve associated with the procedure, and transplantation centers are using it more frequently for the management of haploidentical transplantation complications. AL indicates acute leukemia; CML, chronic myelogenous leukemia; CR, complete remission; CP, chronic phase; AP, accelerated phase; FU, follow-up. Therefore, our results should be interpreted with caution.

(b) Chronic GVHD. Refined GRFS14 was defined as survival without the following events: stage III‐IV aGVHD, severe cGVHD, disease relapse, or death from any cause after haplo‐SCT.

Anderson Cancer Center experience. Recent data also show an immunomodulatory effect of cytokine treatment on donor circulating lymphoid subsets. Our study was not powered to detect potential differences in survival between the two graft sources, because interpretation of the data was mainly limited by the retrospective analysis with the small number of patients. Cancer 2018;124:1428‐37. We thank Emmanuelle Polge from the ALWP‐EBMT office for data collection and cleaning. Meisel R, Laws HJ, Balzer S, Bernbeck B, Kramm C, Schonberger S et al. Considering that human CD34+ cells do not express these molecules, apoptosis is likely mediated by other death ligands.57 Dose escalation of the CD34+ cell population with stem cell activity and CD34+ cell subsets with veto activity in T-cell–depleted megadose PBSC allografts may account for their ability to overcome residual antidonor immune reactivity across major HLA barriers. The first reports using BM, mainly in a non‐myeloablative setting with low‐dose total body irradiation, were associated with low incidence of both aGVHD and cGVHD, counterbalanced by an excess in disease recurrence.21 This prompted some investigators to assess the use of PBSC in this setting, facing the risk of severe GVHD.11 With the aim of analyzing the effect of stem cell sources in patients with acute leukemia, we compared the transplantation outcomes with BM versus PBSC from a haploidentical donor by using data reported to the ALWP‐EBMT registry. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. BM cells were collected from the donors via standard procedures. BM was used in 260 patients, and PBSC were used in 191 patients. Th2 polarization is initiated already in the rhG-CSF–treated donor before host alloantigen activation, resulting in an immunomodulated apheresis product. J Clin Oncol 2005; 23: 5074–5087. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Hematopoietic stem cells traffic constantly between extravascular marrow spaces and PB. The cumulative incidence of acute GVHD at 100 days was 68.4% (95% confidence interval (CI), 50.6–81.0%) in PBSC transplants and 58.8% (95% CI, 46.0–69.6%) in BM transplants (P=0.182) (Figure 1a). The significance level was fixed at .05, and P values were 2‐sided. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation.